Claris Lifesciences is currently trading at Rs. 348.45, up by 21.40 points or 6.54% from its previous closing of Rs. 327.05 on the BSE.
The scrip opened at Rs. 327.90 and has touched a high and low of Rs. 366.00 and Rs. 327.90 respectively. So far 194895 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 430.10 on 16-Dec-2016 and a 52 week low of Rs. 188.00 on 24-Jun-2016.
Last one week high and low of the scrip stood at Rs. 366.00 and Rs. 323.00 respectively. The current market cap of the company is Rs. 1819.83 crore.
The promoters holding in the company stood at 50.13%, while institutions and non-institutions held 28.34% and 21.53% respectively.
Claris Lifesciences (CLL) along with its wholly owned subsidiary Claris Injectables (CIL) has underwent a successful USFDA Pharmacovigilance (PV) audit from May 29 to May 31 with No Observation (i483s).
Claris Lifesciences is engaged in manufacturing of drugs and pharmaceutical products. The Company manufactures and markets products across multiple delivery systems, markets and therapeutic segments, including anesthesia and analgesics, blood products, anti-invective's, critical care, and nephrology.
Company Name | CMP |
---|---|
Redington | 194.70 |
Adani Enterprises | 2229.65 |
Amrapali Industries | 18.23 |
Rashi Peripheral | 371.05 |
Compuage Infocom | 2.58 |
View more.. |